A group of researchers treated 5-FU-resistant colon cancer culture cells with MSI-N1014, a synthesized tetracyclic heterocyclic azathioxanthone, which diminished cell viability and migration and reduced the expression of some oncogenic markers such as mTOR and EGFR, and stem cell markers including LGR5 and β-catenin.[79] This could provide a novel therapeutic strategy to treat 5-FU-resistant colorectal cancer with MSI-N1014, as it demonstrated its therapeutic potential in vitro and in vivo. This evidence concerns the gene LGR5 and colonic neoplasm.